Pharmaceutical company in
Schlieren
41 companies in Pharmaceutical company based in Schlieren — name and year of registration from the commercial register. The list below shows them all.
All 41 companies in Schlieren
Molecular Partners AG
Since 2004 · 101–500 empl.4.9(11)
Molecular Partners AG is a biotechnology company researching and developing therapeutics based on its DARPin protein technology. Its work focuses on targeted radiopharmaceuticals for cancer and DARPin-based immunotherapies.
LimmaTech Biologics AG
Since 2015 · 51–100 empl.4.8(4)
LimmaTech Biologics AG develops vaccines against infections caused by pathogens resistant to antimicrobial treatments. Its work uses a proprietary multivalent vaccine platform and other approaches, with vaccine candidates advancing through clinical development.
Mabylon AG
Since 2011 · 11–20 empl.4.7(3)
Mabylon AG is a biotechnology company that discovers and develops antibody-based therapeutics for allergies, inflammatory disorders and neurological diseases. It identifies and engineers antibodies from human immune repertoires and advances its own drug candidates.
Roche Glycart AG
Since 2000 · 11–20 empl.
Roche Glycart AG operates within Roche Pharma research. Roche’s research site in Schlieren is described as the origin of the company’s glyco-engineering technology.
CONARTIX GmbH
Since 2006 · 1–10 empl.
The core activity of Conartix Health AG is the development, manufacture and marketing of nature-based health products and dietary supplements, particularly based on plant-based substances and prebiotics, with the aim of promoting human health and quality of life.
Redbiotec AG
Since 2006 · 11–20 empl.
Redbiotec AG is a biotechnology company that engineers microorganisms for research and applications in oncology and gene therapy. It also develops and produces proteins and genetic materials for the biopharmaceutical and food industries, and works on therapeutic vaccines, casein proteins and DNA products.
Virometix AG
Since 2009 · 11–20 empl.
Virometix AG is a clinical-stage biotechnology company developing synthetic vaccines against infectious diseases. Its proprietary nanoparticle platform is being used for vaccine candidates including those targeting pneumococcal disease and respiratory syncytial virus (RSV).
Axanton Technology GmbH
Since 2013 · 1–10 empl.
Axanton Technology GmbH develops a technology platform for producing MEMS, a class of therapeutic biomolecules targeting cell-membrane signalling. Its development pipeline includes A-144, a drug candidate intended to affect cell degeneration.
Swiss Bioscience GmbH
Since 2014 · 11–20 empl.
Swiss Bioscience GmbH develops and produces stem cell products from human adipose tissue under cGMP conditions and offers cryopreservation of SVF and hADSCs. The company conducts research and development on stem cells, extracellular vesicles and cell-based applications for regenerative medicine.
NovaGo Therapeutics AG
Since 2015 · 11–20 empl.
NovaGo Therapeutics AG is a biotechnology company developing therapeutic antibodies to promote nerve growth and regeneration in the central nervous system. Its lead candidate, NG004, is being clinically evaluated for acute spinal cord injury, and another development programme targets diabetic retinopathy.
Cellerys AG
Since 2015 · 11–20 empl.
Cellerys AG develops therapies intended to restore immune tolerance in autoimmune diseases, particularly multiple sclerosis. Its CLS12311 approach uses a patient’s own red blood cells coupled with disease-related peptides to promote antigen-specific immune tolerance.
Repertoire Immune Medicines (Switzerland) AG
Since 2018 · 21–50 empl.
Repertoire Immune Medicines (Switzerland) AG develops immune-based medicines for cancer and autoimmune diseases. Its approaches include T-cell receptor bispecific medicines, mRNA cancer vaccines and mRNA-based tolerizing therapies developed using the DECODE platform.
Memo Therapeutics AG
Since 2019 · 21–50 empl.
Memo Therapeutics AG is a biotechnology company developing therapeutic antibodies for viral infections and cancer. Its DROPZYLLA technology identifies and isolates antibodies from immune responses, and its potravitug programme targets BK polyomavirus infections in kidney transplant recipients.
Athebio AG
Since 2019 · 21–50 empl.
Athebio AG is a biotechnology company developing a DARPin platform and drug discovery engine for targeted biotherapeutics. It partners on applications including targeted gene delivery, radiotherapy and immuno-oncology.
DISCO Pharmaceuticals Swiss GmbH
Since 2023 · 21–50 empl.
DISCO Pharmaceuticals Swiss GmbH applies a surfaceome mapping platform to identify cell-surface proteins and protein communities, providing molecular targets for antibody-based cancer therapies. Its initial discovery programs focus on small cell lung cancer and microsatellite-stable colorectal cancer, supporting candidate generation for mono- and bispecific antibodies and antibody–drug conjugates.
InterAx Biotech AG
Since 2016 · 11–20 empl.5.0(2)
The core activity of InterAx Biotech AG is the development of solutions in the field of computer-aided chemistry and systems biology, particularly in the context of GPCR signaling pathways and medicinal chemistry. The company combines expertise in computer science, biology, chemistry, and pharmacy to develop innovative approaches for the development of drugs and therapies.
BiognoSYS AG
Since 2008 · 51–100 empl.5.0(1)
BiognoSYS AG provides contract research services in proteomics for biomarker research and drug development. It also develops and sells proteomics software, peptide kits, and sample preparation reagents.
CUTISS AG
Since 2017 · 21–50 empl.5.0(2)
CUTISS AG develops personalized bioengineered skin tissue therapies for regenerative medicine. Its products include denovoSkin™, a skin graft for wounds requiring skin surgery, and Viticell®, a medical device for restoring skin pigmentation.
Polaroid Therapeutics AG
Since 2023 · 1–10 empl.
Polaroid Therapeutics AG develops biotechnology products for antimicrobial applications in healthcare. Its products include APT™ polymer technology and POLTX_Fiber, a gelling fiber wound dressing with antimicrobial functionality.
HeiQ GrapheneX AG
Since 2019 · 51–100 empl.2.6(5)
HeiQ GrapheneX AG develops a highly porous functional graphene membrane for lithium-metal and anode-free batteries. The material serves as an interface in battery cells and can be supplied as a functional material or integrated into battery solutions.
Topadur Pharma AG
Since 2015 · 11–20 empl.5.0(2)
Topadur Pharma AG develops small-molecule drug candidates for conditions associated with impaired local blood flow and tissue repair. Its pipeline includes therapies for digital ulcers in systemic sclerosis, diabetic foot ulcers and androgenetic alopecia.
Tandem Therapeutics AG
Since 2023 · 1–10 empl.
Tandem Therapeutics AG is a biopharmaceutical company developing therapies for fibrotic diseases and fibrotic cancers. Its platform uses matrix-targeting peptides to address disease-associated changes in the extracellular matrix.
AeoniQ Holding AG
Since 2023 · 101–500 empl.2.6(5)
AeoniQ Holding AG offers the AeoniQ™ technology, a climate-positive continuous cellulosic filament yarn intended to replace polyester and nylon in textile applications.
Proxima Bio GmbH
Since 2026 · 21–50 empl.
Proxima Bio GmbH develops AI-based methods for drug discovery, including tools to predict molecular structures and design biomolecules. Its work combines Neo-1, a model for structure prediction and molecular design, with NeoLink, a platform that generates structural data using cross-linking mass spectrometry.
Baxiva AG
Since 2025 · 1–10 empl.
Baxiva AG is a biotechnology company developing glycoconjugate vaccines against bacterial infections. Its technology links bacterial polysaccharides to virus-like particles and supports vaccine development targeting Gram-negative bacteria. Its lead program focuses on infections caused by Escherichia coli.
C Bertozzi Services
Since 2026 · 1–10 empl.
C Bertozzi Services develops biological therapeutics for diseases of the central nervous system, with a focus on glioblastoma. The company is working on the C-Lock™ platform and the drug candidate InC01, a locally acting cytokine therapy designed for targeted immune activation in the brain.
ALP Bio AG
Since 2026 · 1–10 empl.
ALP Bio AG develops technologies to assess and reduce the immunogenicity risk of therapeutic antibodies. Its platform combines human tonsil-derived organoid models with protein AI for computational screening, experimental validation and antibody redesign.
SuissTech Engineering AG
Since 2011 · 1–10 empl.
SuissTech Engineering AG is a subsidiary of Omnimedica AG.
DAiNA Laboratories AG
Since 2025 · 1–10 empl.
DAiNA Laboratories AG develops approaches for personalized cancer care. The company combines AI with molecular data and biological analyses to characterize tumors individually and support treatment decisions.
Celland AG
Since 2026 · 1–10 empl.
Celland AG offers oral food supplements containing signaling molecules derived from stem cells. The products do not contain added exogenous stem cells and are manufactured according to cGMP standards.
Adugen AG
Since 2015 · 1–10 empl.
AL-S Pharma AG
Since 2016 · 1–10 empl.
SURI BioTech GmbH
Since 2023 · 1–10 empl.
OmnilinX Therapeutics AG
Since 2023 · 1–10 empl.
DiNABIOS AG
Since 2023 · 1–10 empl.
Vivtex GmbH
Since 2023 · 1–10 empl.
SYDRA AG
Since 2024 · 1–10 empl.
syntelios AG
Since 2024 · 1–10 empl.
Elixion BioTech AG
Since 2025 · 1–10 empl.
Livality AG
Since 2025 · 1–10 empl.
OphthaNova Therapeutics AG
Since 2025 · 1–10 empl.
Pharmaceutical company in Schlieren
Pharmaceutical company in the region
Point size by number of companies per place.
Source: commercial register (Zefix) · as of November 7, 2026
Pharmaceutical company in other places
By canton